Intermittent radioligand therapy with Lu-177-PSMA-617 in metastatic castration-resistant prostate cancer patients with favorable characteristics and early response

被引:0
|
作者
Mader, N. [1 ]
Ngoc, C. Nguyen [1 ]
Baumgarten, J. [1 ]
Groener, D. [1 ]
Davis, K. [1 ]
Wichert, J. [1 ]
Tselis, N. [2 ]
Mandel, P. [3 ]
Gruenwald, F. [1 ]
Sabet, A. [1 ]
机构
[1] Univ Hosp Frankfurt, Dept Nucl Med, Frankfurt, Germany
[2] Univ Hosp Frankfurt, Dept Radiooncol, Frankfurt, Germany
[3] Univ Hosp Frankfurt, Dept Urol, Frankfurt, Germany
关键词
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OP-988
引用
收藏
页码:S491 / S492
页数:2
相关论文
共 50 条
  • [41] Antitumor activity of repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
    Rahbar, Kambiz
    Braeuer, Axel
    Yordanova, Anna
    Boegemann, Martin
    Hauser, Stefan
    Eveslage, Maria
    Essler, Markus
    Schafers, Michael
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [42] Cost Utility Analysis of 177Lu-PSMA-617 Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC) in Germany
    Stargardt, T.
    Brinkmann, C.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S827 - S827
  • [43] 177Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer
    Zang, Jie
    Liu, Qingxing
    Sui, Huimin
    Wang, Rongxi
    Jacobson, Orit
    Fan, Xinrong
    Zhu, Zhaohui
    Chen, Xiaoyuan
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (12) : 1772 - 1778
  • [44] 177Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer
    Zang, Jie
    Liu, Qingxing
    Sui, Huimin
    Wang, Rongxi
    Jacobson, Orit
    Zhu, Zhaohui
    Chen, Xiaoyuan
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [45] 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sanli, Yasemin
    Simsek, Duygu Has
    Sanli, Oner
    Subramaniam, Rathan M.
    Kendi, Ayse Tuba
    BIOMEDICINES, 2021, 9 (04)
  • [46] [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer reply
    Hofman, Michael S.
    Violet, John
    Hicks, Rodney J.
    Sandhu, Shahneen
    LANCET ONCOLOGY, 2018, 19 (08): : E373 - E373
  • [47] Response and tolerability after a single dose of Lu-177-PSMA-617 in patients with metastatic castration resistant prostate cancer: a multicenter Study
    Rahbar, Kambiz
    Schmidt, Matthias
    Heinzel, Alexander
    Eppard, Elisabeth
    Yordanova, Anna
    Claesener, Michael
    Bode, Axel
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [48] SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617
    Demirci, Ridvan Arda
    Gulati, Roman
    Hawley, Jessica E.
    Yezefski, Todd
    Haffner, Michael C.
    Cheng, Heather H.
    Montgomery, Robert B.
    Schweizer, Michael T.
    Yu, Evan Y.
    Nelson, Peter S.
    Chen, Delphine L.
    Iravani, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (12) : 1945 - 1951
  • [49] Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
    Kessel, Katharina
    Seifert, Robert
    Weckesser, Matthias
    Roll, Wolfgang
    Humberg, Verena
    Schlack, Katrin
    Boegemann, Martin
    Bernemann, Christof
    Rahbar, Kambiz
    THERANOSTICS, 2020, 10 (17): : 7645 - 7655
  • [50] Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617
    Hojjat Ahmadzadehfar
    Simone Wegen
    Anna Yordanova
    Rolf Fimmers
    Stefan Kürpig
    Elisabeth Eppard
    Xiao Wei
    Carl Schlenkhoff
    Stefan Hauser
    Markus Essler
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1448 - 1454